Teva gets FDA, court nods for generic Prevacid

US sales of Prevacid Delayed-Release Capsules are $2.97 billion a year.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has received two favorable rulings on its generic versions of heartburn and acid reflux drug Prevacid. Takeda Pharmaceuticals Co. Ltd.'s (TSE: 4502) Prevacid is produced as a capsule and as a "solutab" that melts in the mouth.

Teva today announced that the US District Court for the District of Delaware has ruled that its generic version of Prevacid SoluTab dissolvable tablets do not infringe on the US patent of the drug held by Takeda Pharmaceuticals North America Inc. Teva said that IMS sales data showed that brand Prevacid SoluTab sales in the US totaled $500 million in the 12 months through June 2009.

Additionally, the US Food and Drug Administration (FDA) approved Teva's Abbreviated New Drug Application (ANDA) to market its generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid Delayed-Release Capsules in 15 mg and 30 mg doses. Teva will begin shipments today.

Illinios-based Tap Pharmaceutical Inc. is a joint venture of Takeda and Abbott Laboratories Inc. (NYSE: ABT).

According to IMS sales data, US sales of Prevacid Delayed-Release Capsules were $2.97 billion in the 12 months through June 2009.

Teva's share closed at $52.77 on Nasdaq yesterday, giving a market cap of $48 billion. The share rose 0.6% in morning trading on the TASE today to NIS 200.30.

Published by Globes [online], Israel business news - - on November 11, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017